FindTrial
Sign In

POLICYSTIC OVARIAN SYNDROME AND NITRIC OXIDE. EFFECTS OF TREATMENT WITH N-ACETYLCYSTEINE AND ARGININE

POLICYSTIC OVARIAN SYNDROME AND NITRIC OXIDE. EFFECTS OF TREATMENT WITH N-ACETYLCYSTEINE AND ARGININE

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-002091-15-IT
Enrollment
Unknown
Registered
2007-08-07
Start date
2005-11-23
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TO RESTORE A PHYSIOLOGICAL MESTRUAL CICLICITY AND OVULATION INCREASING THE PRODUCTION OF NITRIC OXIDE IN SUBJECTS WITH POLICYSTIC OVARIAN SYNDROME BY MEANS OF ARGININE AND ACETYLCYSTEINE ADMINISTRATION MedDRA version: 9.1 Level: LLT Classification code 10036049 Term: Polycystic ovaries

Interventions

Trade Name: ACETILC.HEX.600*20CPR EFF600MG Pharmaceutical Form: Effervescent tablet INN or Proposed INN: Acetylcysteine CAS Number: 616-91-1 Concentration unit: mg milligram(s) Concentration type: equ

Sponsors

AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: INDUZIONE DI UNA FISIOLOGICA CICLICITA' MESTRUALE CON RIPRISTINO DELL'OVULAZIONE ;Secondary Objective: RIDUZIONE DEL TASSO DI ANDROGENI CIRCOLANTI; INCREMENTO DELLA SENSIBILITA' PERIFERICA ALL'INSULINA E MIGLIORAMENTO DEL PROFILO LIPIDICO; RIDUZIONE DEI PARAMETRI OSSIDATIVI E MIGLIORAMENTO DEGLI INDICI DI FUNZIONALITA' ENDOTELIALE ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026